17 December 2017 in Diabetes, Obesity and Metabolism
Short‐chain fatty acids (SCFAs), produced from fermentation of dietary fibre by the gut microbiota, have been suggested to modulate energy metabolism. Previous work using rodent models has demonstrated that oral supplementation of the SCFA propionate raises resting energy expenditure (REE) by promoting lipid oxidation. The objective of the present study was to investigate the effects of oral sodium propionate on REE and substrate metabolism in humans. Eighteen healthy volunteers (9 women and 9 men; age 25 ± 1 years; body mass index 24.1 ± 1.2 kg/m 2 ) completed 2 study visits following an overnight fast. Tablets containing a total of 6845 mg sodium propionate or 4164 mg sodium chloride were provided over the 180‐minute study period in random order. REE and substrate oxidation were assessed by indirect calorimetry. Oral sodium propionate administration increased REE (0.045 ± 0.020 kcal/min; P = .036); this was accompanied by elevated rates of whole‐body lipid oxidation (0.012 ± 0.006 g/min; P = .048) and was independent of changes in glucose and insulin concentrations. Future studies are warranted to determine whether the acute effects of oral sodium propionate on REE translate into positive improvements in long‐term energy balance in humans.
14 August 2020 in medRxiv
Background: Coronavirus-19 (COVID-19) mortality in hospitalised patients is strongly associated with old age, nursing home residence, male sex and obesity, with a more controversial association with ethnicity and chronic diseases, in particular diabetes mellitus. Further complicating the evaluation of the independent impacts of these risk factors is the failure to control for frailty in the published studies thus far. Aim: To determine the true risk factors for mortality in patients confirmed to have COVID-19 in Croydon needing hospital admission and to evaluate the independence of these risk factors in this group after adjusting for body mass index (BMI) and frailty. Methods: This observational study retrospectively reviewed hospital electronic medical records of 466 consecutive patients who were admitted to Croydon University Hospital confirmed positive by rapid PCR test from 11 th March 2020 to 9 th April 2020. Statistical analysis was performed by multiple unconditional and univariate logistic regression. Results: After multivariate analysis, male sex [OR 1.44 (CI 0.92-2.40)], age (per year) [OR 1.07 (CI 1.05-1.09)], morbid obesity (BMI > 40 kg/m 2 vs reference BMI 18.5-24.9 kg/m 2 ) [OR 14.8 (CI 5.25-41.8)], and nursing home residence (OR 3.01 (CI 1.56-5.79) were independently associated with COVID-19 mortality with no statistically significant association found with chronic diseases or ethnicity. In the non-nursing home population, after adjusting for age and sex, the odds ratio for type 2 diabetes mellitus (T2DM) as a risk factor was 1.64 (CI 1.03-2.61, p = 0.03) and was and was attenuated to 1.30 (CI 0.78-2.18)) after controlling for BMI; the association of mortality with male sex was strengthened [OR 1.66 (CI 0.96-2.87)] and that for ethnic minority patients was weakened [South Asians [from OR 1.30 (CI 0.67-2.53)) to OR 1.21 (CI 0.60-2.46)]; African Caribbeans [from OR 1.24 (CI 0.65-2.34) to OR 1.16 (CI 0.58-2.30)]. There was a borderline but potentially large protective effect (p= 0.09) in patients who were on anticoagulation drugs prior to admission [OR 0.56 (CI 0.28-1.11)]. Conclusion: Our study found no significant effect of ethnicity and chronic diseases as independent risk factors on COVID-19 mortality in Croydon population whereas male sex, high BMI, old age and frailty were found to be independent risk factors. Routine prophylactic treatment with anticoagulant drugs in the high-risk COVID-19 population warrants further prompt investigation.
18 January 2018 in Endocrine Abstracts
Short chain fatty acids (SCFAs), including propionate, are the main metabolic by-products in the fermentation of non-digestible dietary fibre by the gut microbiota. SCFAs have wide-ranging effects in vivo, and their receptors, free fatty acid receptor 2 (FFAR2) and free fatty acid receptor 3 (FFAR3), are expressed at numerous tissue sites. Sodium propionate supplementation has been shown to increase energy expenditure, induce sympathetic neuron action potentials and protect against diet-induced obesity in murine trials. The raised energy expenditure has been accompanied by increased rates of whole-body lipid oxidation. Observations in humans are currently lacking, therefore, the objective of the present study was to investigate the effects of oral sodium propionate supplementation on resting energy expenditure (REE) and lipid oxidation in healthy human volunteers. 18 volunteers (Age: 25±1 y; Body Mass Index 24.1±1.2 kg/m2) were recruited for this randomised, double blind, placebo-controlled, crossover trial. Volunteers received either 6.8 g sodium propionate (Propionate) or 4.2 g sodium chloride (Placebo) capsules following an overnight fast during two standardised 180 min study visits. Indirect calorimetry was used to measure REE, respiratory exchange ratio (RER) and substrate oxidation rates. Levels of circulating propionate were higher in the Propionate trial at 180 min compared with Control (3.04±0.26 vs 5.25±0.65 μmol/l; P=0.005). Propionate increased mean REE (1.25 vs 1.30 kcal/min; P=0.036). This effect was seen in conjunction with a reduction in mean RER (0.88±0.02 vs 0.85±0.02; P=0.040) and corresponding increase in mean whole-body lipid oxidation rates (0.037±0.009 vs 0.049±0.009; P=0.048) over 180 min. The present study observed that oral sodium propionate supplementation increases REE via an increase in lipid oxidation in humans, corroborating findings in animal trials. In humans, >90% of propionate absorbed from the gut lumen undergoes hepatic metabolism, thus it is plausible that these observed effects were primarily due to an increase in hepatic lipid oxidation. Future work may utilise hepatic MR spectroscopy, to investigate the long-term effects of propionate administration on hepatic metabolic processes.